Pharmaceutical Tariffs 2026: 100% Duty on Patented Drugs Under Section 232

A 100% tariff on patented pharmaceutical imports. Not 10%, not 25% — one hundred percent. That's what the April 2, 2026 Executive Order imposes under Section 232 of the Trade Expansion Act. It's the first time pharmaceuticals have been classified as a national security import category.

For the 17 largest pharma companies named in Annex III, the tariff takes effect July 31, 2026 — 86 days from today. For every other pharmaceutical importer, it's September 29, 2026.

But here's the part most coverage buries: the 100% rate is a ceiling, not a floor. Companies can reduce their rate to 20% with an approved onshoring plan, or to 0% with both an onshoring plan and a Most Favored Nation (MFN) pricing agreement. The tariff is a stick. The incentive structure is the carrot.

As of early May 2026, 15 of the 17 named companies have already signed agreements. The question now isn't whether the tariffs will happen — it's who complies, who pays, and what happens to drug prices in the meantime.

Importing pharmaceutical products? Check your HTS Chapter 30 duty rates — the calculator reflects the new Section 232 pharmaceutical structure.

By VatCheck Research Team. Sources: Executive Order of April 2, 2026, White House Fact Sheet, Commerce Department Section 232 guidance, Crowell & Moring analysis, Ropes & Gray analysis, Foley Hoag analysis, AJMC reporting on MFN agreements.

The 17 Named Companies (Annex III)

These companies face the July 31, 2026 accelerated deadline:

| Company | Headquarters | MFN Deal Status (May 2026) | |---|---|---| | AbbVie | North Chicago, IL | Signed | | Amgen | Thousand Oaks, CA | Signed | | AstraZeneca | Cambridge, UK | Signed | | Boehringer Ingelheim | Ingelheim, Germany | Signed | | Bristol Myers Squibb | New York, NY | Signed | | Eli Lilly | Indianapolis, IN | Signed | | EMD Serono (Merck KGaA) | Darmstadt, Germany | Signed | | Genentech (Roche) | South San Francisco, CA | Signed | | Gilead Sciences | Foster City, CA | Signed | | GSK | London, UK | Signed | | Johnson & Johnson | New Brunswick, NJ | Signed | | Merck & Co. | Rahway, NJ | Signed | | Novartis | Basel, Switzerland | Signed | | Novo Nordisk | Bagsværd, Denmark | Signed | | Pfizer | New York, NY | Signed | | Regeneron | Tarrytown, NY | Signed | | Sanofi | Paris, France | Signed |

Key distinction: "Named" in Annex III means an earlier effective date (July 31 vs. September 29), not a higher tariff rate. All pharmaceutical importers face the same 100% rate structure. The earlier deadline was designed to pressure the largest companies into signing MFN pricing agreements first.

As of May 2026, 15 of 17 have signed agreements with the administration. The remaining holdouts face the full 100% rate in 86 days.

The Three-Tier Rate Structure

The tariff isn't binary. It's a graduated incentive system:

Tier 1: 100% Tariff (No Compliance)

Who pays this: Any importer of patented pharmaceuticals or associated pharmaceutical ingredients who has neither an approved onshoring plan nor an MFN pricing agreement.

What it covers:

Patented pharmaceutical products (finished dosage forms)
Active pharmaceutical ingredients (APIs) used in patented drug manufacturing
Pharmaceutical intermediates associated with patented drugs
Primarily classified under HTS Chapter 30 (pharmaceutical products)

What it does NOT cover:

Generic drugs (no patent = no tariff)
Over-the-counter medications that are off-patent
Certain APIs used exclusively in generic manufacturing
Vaccines (exempt under Annex IV public health exception)

Tier 2: 20% Tariff (Approved Onshoring Plan)

Who qualifies: Companies that submit and receive Commerce Department approval for a pharmaceutical manufacturing onshoring plan.

Requirements:

Detailed timeline for establishing or expanding US-based manufacturing capacity
Capital investment commitments (dollar amounts, facility locations)
Employment projections (jobs created, skill levels)
Product-specific manufacturing targets (which drugs will be produced domestically)
Periodic progress reports (quarterly, subject to audit)

Commerce review process:

Submit onshoring plan to the Secretary of Commerce
Commerce publishes criteria in the Federal Register
Review and approval (timeline not yet specified)
Ongoing monitoring with periodic reporting
External audits may be required

Critical detail: The 20% onshoring rate increases to 100% on April 2, 2030 for companies that haven't completed their onshoring commitments by that date. This isn't a permanent discount — it's a 4-year window.

Tier 3: 0% Tariff (Onshoring Plan + MFN Pricing Agreement)

Who qualifies: Companies with both an approved Commerce onshoring plan AND a signed MFN pricing agreement with the Secretary of Health and Human Services.

What the MFN pricing agreement requires:

US prices on covered drugs must not exceed the lowest price charged in any comparable developed nation
Pricing adjustments must be implemented within specified timeframes
HHS monitors compliance through international price comparison databases

Duration: The 0% rate is valid through January 20, 2029. After that date, companies revert to whatever rate their compliance status warrants (likely 20% if onshoring plan is still in progress, or 100% if no plan exists).

Which Drugs Are Actually Affected?

The tariff applies specifically to patented pharmaceuticals. This distinction matters enormously:

Covered (Subject to 100% Tariff)

Brand-name drugs under active patent protection
Biologics with remaining exclusivity periods
APIs used in the manufacture of patented drugs
Combination products where the pharmaceutical component is patented
Drugs where the patent has expired but generic alternatives haven't yet been approved

NOT Covered (Exempt)

Generic drugs with no active patent claims
Over-the-counter medications that are off-patent
Vaccines (public health exemption in Annex IV)
Orphan drugs under certain conditions (limited patient population exclusion)
APIs used exclusively in generic drug manufacturing
Drugs manufactured entirely in the United States (no import, no tariff)

The Patent Ambiguity Problem

The tariff is triggered by patent status, not HTS classification. Two identical molecules classified under the same HTS code could have different tariff rates depending on whether one is patented and the other is generic. CBP has not yet published guidance on how entry specialists should verify patent status at the border.

This is going to create enforcement challenges. Expect CBP to issue further guidance before July 31.

HTS Codes Affected

Most pharmaceutical imports are classified under HTS Chapter 30:

| HTS Code | Description | Likely Tariff Status | |---|---|---| | 3002 | Blood products, vaccines, toxins | Mixed (vaccines exempt, biologics covered) | | 3003 | Medicaments, unmixed, bulk | Covered if patented API | | 3004 | Medicaments, dosage form, retail | Covered if patented drug | | 3006 | Pharmaceutical goods (sutures, blood-grouping, etc.) | Mostly exempt (not patented drugs) |

Also affected (APIs): | HTS Code | Description | Notes | |---|---|---| | 2933-2934 | Heterocyclic compounds | Many pharmaceutical APIs | | 2935-2942 | Sulfonamides, provitamins, hormones, antibiotics | Active ingredients |

Use our HTS code search to find your specific classification, then run it through the tariff calculator to see the full duty structure.

Impact on Drug Prices: What Actually Happens

A 100% tariff on pharmaceutical imports sounds catastrophic for drug prices. The reality is more nuanced — but still significant.

Why Prices Won't Simply Double

Most named companies are signing MFN deals — they'll pay 0% tariff, not 100%
Many drugs are manufactured domestically — no import = no tariff
Generic drugs are exempt — the generic market (90%+ of prescriptions) is largely unaffected
Biologics are increasingly manufactured in the US — the trend was already underway

Where Prices WILL Be Affected

Smaller pharma companies that don't sign MFN deals face the full 100% after September 29
Specialty drugs with no domestic manufacturing alternative have no easy path to 0%
API-dependent generics where the active ingredient is imported from India/China — technically the generic is exempt but API cost increases will flow through
Hospital drugs with thin margins — even a 20% tariff creates pricing pressure

The Real Economic Play

The tariff isn't designed to collect revenue. It's designed to force two outcomes:

MFN pricing — US drug prices drop to international levels (the real goal)
Onshoring — pharmaceutical manufacturing moves to the US (the stated goal)

Most major companies will choose Option 1 (sign the MFN deal, get 0% tariff) rather than actually move manufacturing. The onshoring plan is the slower, more expensive path. The MFN pricing agreement is the fast lane to 0%.

How This Interacts With Other Tariffs

Pharmaceutical Tariff + Section 122

Pharmaceuticals are exempt from Section 122 (listed in Annex II exemptions). So there's no stacking concern here. When Section 122 expires on July 24, it has zero effect on pharmaceutical imports.

Pharmaceutical Tariff + Section 301

If a patented drug is manufactured in China, it could theoretically face both the Section 232 pharmaceutical tariff AND Section 301 tariffs. The combined rate would be extraordinary — potentially 125%+ on a single import.

In practice, very few finished pharmaceutical products enter from China. APIs from China are more common, and these would face the combined rate if they're used in patented drug manufacturing.

Pharmaceutical Tariff + MFN Base Rate

The pharmaceutical Section 232 tariff is additive to the MFN base rate. Most pharmaceutical HTS codes have very low or zero MFN rates, so the base rate impact is negligible — it's the 100% Section 232 that matters.

Timeline: What Happens When

| Date | Event | Who's Affected | |---|---|---| | April 2, 2026 | Executive Order signed | All pharmaceutical importers (notice) | | May 2026 | Commerce publishes onshoring criteria | Companies preparing plans | | July 24, 2026 | Section 122 expires | No pharma impact (already exempt) | | July 31, 2026 | Tariff effective for 17 named companies | AbbVie through Sanofi | | September 29, 2026 | Tariff effective for all other importers | Everyone else | | April 2, 2030 | 20% onshoring rate increases to 100% | Companies with incomplete onshoring | | January 20, 2029 | 0% MFN pricing rate expires | Companies with MFN agreements |

What Importers Should Do Now

If You Import Patented Pharmaceuticals:

Verify your patent exposure — which of your imported products are patented vs. generic?
Engage with Commerce on onshoring plan criteria (not yet published as of May 2026)
Model your costs at 100%, 20%, and 0% — what's your break-even for each compliance tier?
Review your supply chain — can any manufacturing be shifted to US facilities before July 31?
Track MFN pricing guidance from HHS — what "most favored nation" pricing means in practice

If You Import APIs:

Determine patent linkage — is your API used in patented drug manufacturing?
Document generic-only use — if your API feeds only generic production, prepare evidence for CBP
Diversify sourcing — if currently sourcing from China, consider India or domestic alternatives to avoid Section 301 stacking

If You're a Smaller Company (Not Annex III):

You have until September 29 — use the extra 60 days to prepare
Watch what the 17 named companies do — their compliance path will establish precedents
The MFN pricing agreement is your fastest route to 0% — onshoring takes years; MFN signing can happen in weeks

Enforcement: What We Don't Know Yet

Several critical implementation questions remain unanswered as of May 2026:

How will CBP verify patent status at entry? No guidance published yet
What happens when a patent expires mid-shipment? Entry date vs. manufacturing date?
How are combination products treated? One patented ingredient + five generic ingredients = 100% on the whole thing?
Who monitors MFN pricing compliance? HHS hasn't published monitoring procedures
What's the threshold for "associated" APIs? If an API has dual use (patented and generic), does the tariff apply?

Expect CBP CSMS bulletins and Federal Register notices addressing these questions before July 31. We'll update this guide as implementation guidance is issued.

Frequently Asked Questions

Will pharmaceutical tariffs raise drug prices for consumers?

For most prescriptions, no — generic drugs (90%+ of prescriptions filled) are exempt. For patented brand-name drugs, the impact depends on whether the manufacturer signs an MFN pricing agreement. Ironically, the MFN agreement that eliminates the tariff also requires lower US prices. Companies choosing the 0% route will actually reduce prices.

Which drug companies are affected first?

The 17 companies listed in Annex III face the July 31, 2026 deadline: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi. As of May 2026, 15 of 17 have signed MFN agreements.

How can pharmaceutical companies reduce their tariff rate?

Two paths: (1) Submit an approved onshoring plan to Commerce → rate drops from 100% to 20%. (2) Add an MFN pricing agreement with HHS → rate drops to 0%. Both require ongoing compliance and reporting. The 0% rate expires January 20, 2029.

Are generic drugs subject to the pharmaceutical tariff?

No. The tariff applies only to patented pharmaceuticals and their associated active pharmaceutical ingredients. Generic drugs with no active patent claims are exempt. However, if a generic manufacturer imports APIs that are also used in patented drug production, those APIs could be subject to the tariff.

When do pharmaceutical tariffs take effect?

July 31, 2026 for the 17 named companies in Annex III. September 29, 2026 for all other pharmaceutical importers. Companies with approved onshoring plans and MFN pricing agreements face 0% from day one.

Can pharmaceutical tariffs be refunded through the CAPE portal?

No. The CAPE portal handles refunds of IEEPA tariffs that were struck down by the Supreme Court. Section 232 pharmaceutical tariffs are a separate legal authority and are not eligible for CAPE refunds.

Last updated: May 2026. Pharmaceutical tariff implementation is evolving rapidly. Commerce onshoring criteria and CBP enforcement guidance are pending. For current rates on HTS Chapter 30 codes, use our calculator. Track developments at BIS.gov and monitor Federal Register notices.